Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614543 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRGRIK1GRIK2HSD17B10 | |
| SCHEMBL5792188 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRGRIK1GRIK2HSD17B10 | |
| SCHEMBL1486834 | 0.88 | FFAR3 (0.38) | ALDH1A1TSHRGRIK1GRIK2TDP1 | |
| SCHEMBL7601534 | 0.83 | GRIK1 (0.38) | ALDH1A1TSHRGRIK1GRIK2HSD17B10 | |
| SCHEMBL11650762 | 0.83 | GRIK1 (0.38) | ALDH1A1TSHRGRIK1GRIK2HSD17B10 | |
| SCHEMBL7601525 | 0.83 | GRIK1 (0.38) | ALDH1A1TSHRGRIK1GRIK2HSD17B10 | |
| SCHEMBL6552881 | 0.81 | ALDH1A1 (0.38) | ALDH1A1TSHRGRIK1GRIK2HSD17B10 | |
| SCHEMBL2362374 | 0.78 | GRIK1 (0.36) | GRIK1GRIK2FFAR3 | |
| SCHEMBL2362380 | 0.78 | GRIK1 (0.36) | GRIK1GRIK2FFAR3 | |
| SCHEMBL11600639 | 0.78 | EP300 (0.53) | HSD17B10TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309599-B2 | Synthesis of FR901464 and analogs with antitumor activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110086909-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH-- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-04-14 | — | — | US | disclosed |
| US-7825267-B2 | Synthesis of FR901464 and analogs with antitumor activity | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080096879-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | UNIVERSITY OF PITTSBURGH-- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096879-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | ALDH1A1 3890/4885TSHR 1762/4885GRIK1 3546/4885 |
| US-20110086909-A1 | SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY | RBM17, SF3B1, RTCB | ALDH1A1 3890/4885TSHR 1762/4885GRIK1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.